SynthesisPharmacogenomics2019
A systematic review of genome-wide association studies of antipsychotic response.
Synthesis in Pharmacogenomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: a systematic review and meta-analysis.BMC psychiatry · 2024Pooled it
- Analysis of genetic and clinical factors associated with buprenorphine response.Drug and alcohol dependence · 2021Pooled it
- Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth.Clinical pharmacology and therapeutics · 2026Article
- Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks.European archives of psychiatry and clinical neuroscience · 2026Article
- Antipsychotic use in bipolar disorder: clinical and genomic correlates- a Mayo clinic bipolar disorder biobank study.International journal of bipolar disorders · 2025Article
- Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force.Bipolar disorders · 2025Review
- Antipsychotic Use in Bipolar Disorder: Clinical and Genomic Correlates- A Mayo Clinic Bipolar Disorder Biobank Study.Research square · 2025Article
- Genetic determinants of antidepressant and antipsychotic drug response.European archives of psychiatry and clinical neuroscience · 2025Article
- Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.Molecular psychiatry · 2025Article
- Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study.Frontiers in pharmacology · 2024Article
- Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19.Journal of personalized medicine · 2023Article
- The Dysregulated MAD in Mad: A Neuro-theranostic Approach Through the Induction of Autophagic Biomarkers LC3B-II and ATG.Molecular neurobiology · 2023Review
- Genomic selection analysis of morphological and adaptation traits in Chinese indigenous dog breeds.Frontiers in veterinary science · 2023Article
- Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.Methods in molecular biology (Clifton, N.J.) · 2022Article
- TNIK influence the effects of antipsychotics on Wnt/β-catenin signaling pathway.Psychopharmacology · 2021Article
- Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia.JAMA network open · 2020Article
- Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.Human genomics · 2020Article
- Solute Carrier Family 1 (Frontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. 14 studies met our inclusion criteria, ten of which examined antipsychotic response using quantitative rating scales to measure symptom improvement. 15 genome-wide significant loci were identified, seven of which were replicated in other antipsychotic GWAS publications: CNTNAP5, GRID2, GRM7, 8q24 (KCNK9), PCDH7, SLC1A1 and TNIK. Notably, four replicated loci are involved in glutamatergic pathways. Additional validation and evaluation of the biological significance of these markers is warranted. These markers should also be evaluated for clinical utility, especially in the context of other validated pharmacogenomic variants (e.g., CYP450 genes). These findings may generate new avenues for development of novel antipsychotic treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.